Literature DB >> 3946323

Antibody response to pneumococcal vaccine in children aged 5 to 15 years.

J C Paton, I R Toogood, R A Cockington, D Hansman.   

Abstract

The type-specific antibody response of 99 healthy children, aged 5 to 15 years, to a 14-valent pneumococcal vaccine was determined and analyzed according to age at the time of vaccination. The response to the majority of the serotypes, including the important "pediatric" types 6A, 18C, and 19F, appeared to plateau in the 8- to 10-year-old age group, whereas for types 14 and 23F, which are also important in children, the response continued to improve with age to ages 13 to 15 years. The antibody response of a group of 23 children, aged 5 to 15 years, with various hematologic disorders (12 of whom had undergone splenectomy) was also determined and compared with that of the healthy children. For all serotypes the antibody response was similar in the two groups.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3946323     DOI: 10.1001/archpedi.1986.02140160053031

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  11 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

Review 2.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Regulation of the antibody repertoire through control of HCDR3 diversity.

Authors:  H W Schroeder; G C Ippolito; S Shiokawa
Journal:  Vaccine       Date:  1998 Aug-Sep       Impact factor: 3.641

4.  Serotypes and resistance patterns of Streptococcus pneumoniae causing systemic disease in northern Norway.

Authors:  T Magnus; B M Andersen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

5.  Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.

Authors:  M D Snape; D F Kelly; S Lewis; C Banner; L Kibwana; C E Moore; L Diggle; T John; L M Yu; R Borrow; A Borkowski; C Nau; A J Pollard
Journal:  BMJ       Date:  2008-06-05

6.  IgG subclass specific antibody response in recurrent bronchitis.

Authors:  F de Baets; R Pauwels; I Schramme; J Leroy
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

7.  Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex.

Authors:  P P Vella; S Marburg; J M Staub; P J Kniskern; W Miller; A Hagopian; C Ip; R L Tolman; C M Rusk; L S Chupak
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

8.  Mutation of luxS of Streptococcus pneumoniae affects virulence in a mouse model.

Authors:  Uwe H Stroeher; Adrienne W Paton; A David Ogunniyi; James C Paton
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

9.  Age-specific immunoglobulin g (IgG) and IgA to pneumococcal protein antigens in a population in coastal kenya.

Authors:  Catherine Laine; Tabitha Mwangi; Claudette M Thompson; Jacktone Obiero; Marc Lipsitch; J Anthony G Scott
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

10.  Serotype-specific immune unresponsiveness to pneumococcal conjugate vaccine following invasive pneumococcal disease.

Authors:  Ray Borrow; Elaine Stanford; Pauline Waight; Matthew Helbert; Paul Balmer; Rosalind Warrington; Mary Slack; Robert George; Elizabeth Miller
Journal:  Infect Immun       Date:  2008-09-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.